RenovoRx to highlight TAMP platform at JonesTrading KOL webinar on Aug 13, 2026

RenovoRx, Inc.

RenovoRx to participate in JonesTrading KOL webinar on pancreatic cancer on Aug 13, 2026 at 1:30 p.m. ET.
RenovoCath sales of ~$1.1M in 2025 and record $563K in Q1 2026.
Full enrollment in Phase III TIGeR-PaC trial expected very near term; final data readout mid to late 2027.
IAG (intra-arterial gemcitabine via RenovoCath) has Orphan Drug Designation for pancreatic and bile duct cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.